Back

Personalized approach to cardiovascular risk stratification: a randomized controlled trial evaluating the effectiveness of an AI-developed diet versus a standard mediterranean diet

31 August 2025 (08:15 - 09:00)
Organised by: Logo
Congress Presentation Part of: Risk stratification models: leveraging digital health for better outcomes Artificial Intelligence ESC Professional Premium Access ESC Congress 2025 European Society of Cardiology

About the speaker

Photo
Mr Bekzod Rozibaev

Tashkent (Uzbekistan)

7 More presentations in this session

Presentation thumbnail
Comparing machine learning models with established risk scores in predicting bleeding and ischaemic stroke in patients with atrial fibrillation undergoing transcatheter aortic valve implantation
Doctor G. Dangas (New York, US)
Abstract Slides
Presentation thumbnail
Prediction of atrial fibrillation from the electrocardiogram in the community using deep learning
Doctor L. Brant (Belo Horizonte, BR)
Abstract Slides Video
Presentation thumbnail
Leveraging AI and clinical guidelines to identify undiagnosed and under-treated CKD patients for treatment optimisation
Ms A. Veldman (The Hague, NL)
Abstract Slides Video
Presentation thumbnail
Quick and easy multi-pathology cardiovascular disease detection with an artificial intelligence-enabled stethoscope: multi-centre prospective validation study in secondary care
Doctor P. Bachtiger (London, GB)
Abstract Slides Video
Presentation thumbnail
Efficiency of an artificial intelligence powered electrocardiogram model for early detection of occlusion myocardial infarction in acute coronary syndrome: a multicenter cohort study
Doctor C. Militello (Rome, IT)
Abstract Slides Video

Access the full session

Session thumbnail
Risk stratification models: leveraging digital health for better outcomes

The Event

Event poster

ESC Congress 2025

31 August 2025 08:15 CET
You may be interested in
thumbnail
Congress Presentation
An isocaloric high fat diet enriched with saturated compared to polyunsaturated fat has a more detrimental effect on clinical cardiometabolic risk factors in healthy humans
thumbnail
Congress Session
Innovation and integration in cardiovascular medicine
thumbnail
Congress Presentation
SURMOUNT-5: Tirzepatide compared to Semaglutide in obesity for 10-year CVD risk reduction

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources